Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

USP Nitrosamine Impurities Chapter Reflects Coordination With EU As Well US Agencies

Dec 06 2021

• By Shannon Brown

• Source: Alamy

Related Content

As Recalls Multiply, EU Agency Studies How To Rid Chinese Firm’s Valsartan API Of Probable Carcinogen

Jul 20 2018

US FDA Expectations For Removing Nitrosamines From All APIs, Drug Products

Sep 02 2020

USP Proposes Analytical Methods For Drug Makers To Detect Nitrosamine Impurities

Sep 08 2020

Perrigo Among Firms Requesting Delay In Conducting US Nitrosamine Risk Assessments

Dec 16 2020

US FDA’s 30-Day Extension For Nitrosamine Assessments Short Of Industry Recommendation

Feb 25 2021

US FDA Suggests Adding Antioxidants To Drug Formulations To Mitigate Nitrosamine Risks

Nov 23 2021

Additional Topics

International Europe United States Ingredients Guidance Documents OTC Drugs Commercial Consumer Drug Approval Standards Drug Review FDA Manufacturing Policy Regulation Research & Development Supply Chain

More from Ingredients & Safety

More from HBW Insight

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window